Related references
Note: Only part of the references are listed.Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study
B. L. Samuels et al.
ANNALS OF ONCOLOGY (2013)
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
Jean-Yves Blay et al.
BMC CANCER (2013)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Axel Le Cesne
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study
M. Leahy et al.
ANNALS OF ONCOLOGY (2012)
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
Federica Grosso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
New Systemic Therapy Options for Advanced Sarcomas
Winette T. A. van der Graaf et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2012)
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne et al.
EUROPEAN JOURNAL OF CANCER (2012)
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2012)
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
Luis Paz-Ares et al.
INVESTIGATIONAL NEW DRUGS (2012)
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
Axel Le Cesne et al.
INVESTIGATIONAL NEW DRUGS (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Trends in Survival for Patients With Metastatic Soft-Tissue Sarcoma
Antoine Italiano et al.
CANCER (2011)
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
Juliette Thariat et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers
Roberta Sanfilippo et al.
GYNECOLOGIC ONCOLOGY (2011)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
F. Grosso et al.
ANNALS OF ONCOLOGY (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Jean-Yves Blay et al.
CLINICAL CANCER RESEARCH (2008)
Role of homologous recombination in trabectedin-induced DNA damage
M. Tavecchio et al.
EUROPEAN JOURNAL OF CANCER (2008)
Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex
Josee Guirouilh-Barbat et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
Jose A. Casado et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
Daniele Grazziotin Soares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
F. Grosso et al.
EUROPEAN JOURNAL OF CANCER (2006)
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
A Yovine et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients
AT van Oosterom et al.
EUROPEAN JOURNAL OF CANCER (2002)
Share Paper
